<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dengue virus infection: Pathogenesis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dengue virus infection: Pathogenesis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dengue virus infection: Pathogenesis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen J Thomas, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan L Rothman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Substantial gaps remain in the comprehensive understanding of the pathogenesis of dengue virus (DENV) infections. In large part, this limitation is related to the lack of a suitable animal model of disease [<a href="#rid1">1</a>]. Rhesus monkeys develop RNAemia and viremia similar in a pattern to humans after DENV challenge but do not develop clinical disease. Careful epidemiologic and experimental challenge studies in humans have provided valuable information on DENV infection, but detailed data on virus distribution in vivo are available only from small numbers of patients with more severe disease, unusual manifestations, or the later stages of infection. Little pathogenetic information is available concerning milder infections, which constitute the vast majority of cases.</p><p class="headingAnchor" id="H2"><span class="h1">THE DENGUE VIRUS REPLICATION CYCLE</span><span class="headingEndMark"> — </span>DENVs are members of the family Flaviviridae genus <em>Flavivirus</em>. They are small, enveloped viruses containing a single-strand RNA genome of positive polarity [<a href="#rid2">2</a>]. DENVs infect a wide range of human and nonhuman cell types in vitro. Viral replication involves the following steps:</p><p class="bulletIndent1"><span class="glyph">●</span>Attachment to the cell surface</p><p class="bulletIndent1"><span class="glyph">●</span>Entry into the cytoplasm</p><p class="bulletIndent1"><span class="glyph">●</span>Translation of viral proteins</p><p class="bulletIndent1"><span class="glyph">●</span>Replication of the viral RNA genome</p><p class="bulletIndent1"><span class="glyph">●</span>Formation of virions (encapsidation)</p><p class="bulletIndent1"><span class="glyph">●</span>Release from the cell</p><p></p><p>Binding of dengue virions to cells, which is mediated by the major viral envelope (E) glycoprotein, is critical for infectivity. The determination of the three-dimensional structures of the dengue E glycoprotein and the intact virion has facilitated the understanding of this process [<a href="#rid3">3-5</a>]. DENVs bind via the E glycoprotein to viral receptors on the cell surface, which may include heparan sulfate or lectins such as DC-SIGN and CLEC5A [<a href="#rid6">6-8</a>]; they can also bind to cell surface immunoglobulin receptors in the presence of antibodies to the E glycoprotein or precursor membrane (pre-M) protein, as described further below [<a href="#rid9">9</a>].</p><p>Following fusion of viral and cell membranes in acidified endocytic vesicles, the viral RNA enters the cytoplasm. The viral proteins are then translated directly from the viral RNA as a single polyprotein, which is cleaved to yield the three structural and seven nonstructural proteins [<a href="#rid2">2</a>]. Cleavage of several of the viral proteins requires a functional viral protease encoded in the nonstructural protein NS3. The nonstructural protein NS5 is the viral RNA-dependent RNA polymerase, which assembles with several other viral proteins and several host proteins to form the replication complex. This complex transcribes the viral RNA to produce negative-strand viral RNA, which serves as the template for the production of the viral genomic RNA.</p><p>The assembly and budding of progeny virions is still poorly understood. The pre-M structural protein is cleaved by a cellular enzyme, furin, as one of the final steps in maturation of progeny virions [<a href="#rid2">2</a>]. Cleavage of the pre-M protein enhances the infectivity of the virions 100-fold.</p><p class="headingAnchor" id="H3"><span class="h1">COURSE OF INFECTION</span><span class="headingEndMark"> — </span>The course of DENV infection is characterized by early events, dissemination, and the immune response and subsequent viral clearance  (<a class="graphic graphic_figure graphicRef63173" href="/d/graphic/63173.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H4"><span class="h2">Early events</span><span class="headingEndMark"> — </span>DENV is introduced into the skin when an infected mosquito, most commonly <em>Aedes aegypti</em>, takes a blood meal from a host. The spread of virus early after injection has been studied in rhesus monkeys [<a href="#rid10">10</a>]. During the first 24 hours, virus could only be isolated from the injection site. The major cell type infected was not defined; in humans, Langerhans cells, myeloid dendritic cells, mast cells, and dermal fibroblasts have all been proposed to be target cells for DENV infection in the skin based on their permissiveness to infection in vitro [<a href="#rid11">11</a>]. In rhesus monkeys, virus was detected in regional lymph nodes 24 hours after infection [<a href="#rid10">10</a>]. Macrophages and dendritic cells were demonstrated to be early cellular targets for DENV infection in a mouse model deficient in both type I and type II interferon (IFN) receptors [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Dissemination</span><span class="headingEndMark"> — </span>In rhesus monkeys, viremia begins two to six days after subcutaneous injection and lasts for three to six days. In early studies of humans infected with near wild type DENV strains, viremia began approximately one day later than in monkeys, but the duration of viremia was similar [<a href="#rid13">13</a>]. In a subsequent experimental human infection study, an under-attenuated DENV-1 strain had a mean incubation period was 5.9 days (range five to nine days), mean time of viremia was 6.8 days (range three to nine days), and mean peak RNAemia of 1.6 x 10<sup>7</sup> genome equivalents (GE)/mL (range 4.6 x 10<sup>3</sup> to 5 x 10<sup>7</sup> GE/mL) [<a href="#rid14">14</a>]. In a study of natural human infection, viremia was detectable 6 to 18 hours before the onset of symptoms and ended around the time fever resolved [<a href="#rid15">15</a>].</p><p>In rhesus monkeys during the period of viremia, virus was frequently detected in lymph nodes distant from the site of inoculation and less commonly from spleen, thymus, lung, and bone marrow [<a href="#rid10">10</a>]. Virus was also isolated from peripheral blood leukocytes at the end of the viremic period and sometimes for one day after.</p><p>The distribution of virus in humans has been studied in blood, biopsy, and autopsy specimens from patients with natural DENV infection. Infection of peripheral blood mononuclear cells persists beyond the period of detectable viremia [<a href="#rid16">16-18</a>]. Conflicting data have been published regarding the principal infected cell type in the peripheral blood. An older study reported more frequent isolation of infectious virus from the adherent cell population than the nonadherent population, suggesting that monocytes are the primary target cell for infection [<a href="#rid16">16</a>]. A similar conclusion was reached in a study using flow cytometry, which reported the detection of dengue viral antigen in a very high percentage of circulating monocytes [<a href="#rid18">18</a>]. However, an earlier study using flow cytometry reported that the majority of cell-associated virus was contained in the CD20+ (B lymphocyte) fraction [<a href="#rid17">17</a>]. Another study using polymerase chain reaction found the highest levels of dengue viral RNA in B cells but could not exclude passive binding as an explanation [<a href="#rid19">19</a>].</p><p>The yield of DENV from tissues obtained at autopsy has generally been low. However, in one study using the most sensitive techniques for virus isolation, virus was isolated most often (4 of 16 cases) from liver tissue [<a href="#rid20">20</a>]. Antigen staining has suggested that the predominant cell types infected are macrophages in the skin [<a href="#rid21">21</a>] and Kupffer cells in the liver [<a href="#rid22">22,23</a>]; DENV antigens have also been detected in hepatocytes in some cases [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Immune response and viral clearance</span><span class="headingEndMark"> — </span>Both innate and adaptive immune responses induced by DENV infection are likely to play a role in the clearance of infection  (<a class="graphic graphic_figure graphicRef134436" href="/d/graphic/134436.html" rel="external">figure 2</a>) [<a href="#rid25">25</a>]. Infection of human cells in vitro induces antiviral responses, including the production of interferons [<a href="#rid26">26</a>]. Consistent with these observations, elevated serum levels of IFN-alpha have been demonstrated in children with dengue [<a href="#rid27">27</a>].</p><p>The role of these cytokine responses is uncertain. Interferon inhibits DENV infection in vitro. In addition, DENV–infected cells are susceptible to lysis by natural killer cells in vitro [<a href="#rid28">28</a>]. However, DENV proteins are able to inhibit both the production of interferons and their antiviral function in infected cells [<a href="#rid29">29,30</a>]. In several studies, the expression of genes associated with type I interferon signaling was significantly lower in patients with dengue shock syndrome (DSS) than in patients without DSS [<a href="#rid31">31,32</a>]. Whether attenuated interferon responses are the result or cause of severe dengue disease is unknown.</p><p>The antibody response to DENV infection is primarily directed at serotype-specific determinants, but there is a substantial level of serotype-cross-reactive antibodies  (<a class="graphic graphic_figure graphicRef122397" href="/d/graphic/122397.html" rel="external">figure 3</a>). E, precursor membrane (pre-M), and NS1 are the principal viral proteins that are targeted. In vitro, E protein-specific antibodies can mediate neutralization of infection, direct complement-mediated lysis or antibody-dependent cellular cytotoxicity of DENV-infected cells, and block virus attachment to cell receptors [<a href="#rid2">2</a>]. Pre-M–specific antibodies only bind to virions that have not fully matured and have remaining uncleaved pre-M protein. NS1 is not found in the virion; NS1-specific antibodies are therefore incapable of neutralization of virus infection but can direct complement-mediated lysis of infected cells [<a href="#rid33">33</a>].</p><p>The basis of neutralization of virus by antibody is not well understood. Neutralization clearly requires a threshold level of antibodies; when the concentration of antibodies is below this threshold, the uptake of antibody-bound virus by cells that express immunoglobulin (Ig) receptors is paradoxically increased, a process termed antibody-dependent enhancement (ADE) of infection [<a href="#rid34">34,35</a>]. Since monocytes, the putative cellular targets of DENV infection in vivo, express immunoglobulin receptors and manifest ADE in vitro, this phenomenon is thought to be highly relevant in natural DENV infections (see below). In rhesus monkeys, passive transfer of low levels of dengue-immune human sera or a humanized chimpanzee DENV–specific monoclonal antibody resulted in a 2- to 100-fold increase in dengue-2 or dengue-4 viremia titers as compared with control animals [<a href="#rid36">36,37</a>]. An increase in viral titers in blood and tissues and enhanced disease were also observed after passive transfer of low levels of DENV-specific antibody in mice lacking interferon receptors [<a href="#rid38">38</a>]. DENV entry via ADE has also been found to suppress innate immune responses in infected monocytes in vitro [<a href="#rid9">9</a>].</p><p>One study characterized 301 human DENV-specific monoclonal antibodies [<a href="#rid39">39</a>]. Pre-M-specific antibodies represented a larger fraction of the monoclonal antibodies detected than antibodies directed at E or NS1. Pre-M-specific antibodies showed poor neutralization of infection in vitro but could mediate ADE.</p><p>The T lymphocyte response to DENV infection also includes both serotype-specific and serotype-cross-reactive responses [<a href="#rid40">40</a>]. DENV-specific CD4+ and CD8+ T cells can lyse DENV-infected cells in vitro and produce cytokines such as IFN-gamma, tumor necrosis factor (TNF)-alpha, and lymphotoxin. In vitro, IFN-gamma can inhibit DENV infection of monocytes. However, IFN-gamma also enhances the expression of Ig receptors, which can augment the antibody-dependent enhancement of infection [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Primary versus secondary infection</span><span class="headingEndMark"> — </span>Infection with one of the four serotypes of DENV (primary infection) generally provides long-lasting immunity to infection with a virus of the same serotype [<a href="#rid13">13</a>]. In contrast, immunity to the other dengue serotypes is transient, and individuals can subsequently be infected with another dengue serotype (secondary infection). Two prospective cohort studies found that the interval between primary and secondary DENV infections was significantly longer among children who experienced a symptomatic secondary infection than those who had a subclinical secondary infection, suggesting that heterotypic protective immunity wanes gradually over one to two years [<a href="#rid42">42,43</a>].</p><p>In one report, the distribution of DENV in secondary infections was evaluated in eight rhesus monkeys [<a href="#rid10">10</a>]. The onset and duration of viremia were similar to primary infections. Autopsy specimens from six monkeys yielded virus somewhat more frequently from various tissues than specimens from primary infections. Another study found higher plasma virus titers in secondary than primary dengue-2 virus infections but not in secondary infections with DENVs of the other serotypes [<a href="#rid44">44</a>].</p><p>There is little information from human studies to allow comparisons of virus distribution or titer in primary and secondary infections. Several studies have reported that higher peak plasma virus titers in secondary dengue infections were associated with more severe illness [<a href="#rid45">45-47</a>]. Two studies failed to demonstrate higher viremia titers in patients with secondary dengue infections than in patients with primary dengue infections [<a href="#rid48">48,49</a>], but a study using quantitative reverse-transcription polymerase chain reaction reported higher viral RNA levels in CD14+ monocytes among dengue fever patients with secondary infections compared with dengue fever patients with primary infections [<a href="#rid19">19</a>].</p><p>The kinetics of DENV-specific antibodies in secondary dengue infections differ from those of primary dengue infections in several ways.</p><p class="bulletIndent1"><span class="glyph">●</span>Low concentrations of antibodies to the virus serotype causing the secondary infection are present before exposure to the virus. As a result, antibody-dependent enhancement of infection could occur early in secondary DENV infections. Consistent with this hypothesis, two separate analyses of data from longitudinal cohort studies of children in Nicaragua and Thailand found that the risk of more severe dengue illness was highest within a narrow range of pre-existing anti-DENV antibody titers [<a href="#rid50">50,51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concentrations of DENV-specific antibodies increase earlier in secondary infection, reach higher peak titers, and have a lower IgM:IgG ratio, suggestive of an anamnestic response. Thus, the levels of DENV-specific antibodies are much higher during the late stage of viremia in secondary infections, with greater potential for forming immune complexes of dengue virions and activating complement.</p><p></p><p>The kinetics of the T lymphocyte response in secondary infections also would be expected to differ from those of primary infections, with an earlier onset and higher level of DENV-specific T lymphocyte proliferation and cytokine production in secondary infections. Studies of circulating T lymphocytes during acute secondary infections have shown a high percentage of cells expressing markers of activation and high frequencies of dengue antigen-specific cells, consistent with this hypothesis [<a href="#rid52">52-55</a>]. However, a study that compared the frequencies of T cells specific for an immunodominant dengue epitope between symptomatic primary and secondary DENV infections found no significant differences [<a href="#rid56">56</a>].</p><p>The severity of dengue disease has been correlated with the level and quality of the DENV-specific T lymphocyte responses in some studies [<a href="#rid53">53,54</a>] but not in others [<a href="#rid56">56,57</a>].</p><p>Some serotype-cross-reactive T cells present after primary infection display qualitatively altered functional responses to other dengue serotypes [<a href="#rid40">40</a>]. In one prospective cohort study, specific T cell responses prior to secondary DENV infection were associated with the subsequent occurrence of dengue hemorrhagic fever, such as production of TNF-alpha in response to stimulation with dengue antigens [<a href="#rid58">58</a>]. In contrast, higher frequencies of CD4+ T cells producing IFN-gamma or interleukin (IL)-2 in response to stimulation with dengue antigens were associated with subclinical dengue infection, suggesting a protective effect as well [<a href="#rid59">59</a>]. In a separate study, the secretion of IL-6, IL-15, and macrophage chemotactic protein 1 in response to in vitro stimulation with DENV was associated with symptomatic dengue infection whereas the secretion of other cytokines, including IL-12 and CCL5/RANTES (Regulated on Activation, Normal T cell Expressed, and Secreted) was associated with subclinical infection, pointing to the potential for either protective or pathologic immune response profiles [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H8"><span class="h1">FACTORS INFLUENCING DISEASE SEVERITY</span><span class="headingEndMark"> — </span>Most DENV infections produce mild, nonspecific symptoms or classic dengue fever (DF). Severe dengue, dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS), occurs in less than 1 percent of all DENV infections. Thus, considerable attention has been focused upon understanding the risk factors for DHF  (<a class="graphic graphic_table graphicRef58587" href="/d/graphic/58587.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H9"><span class="h2">Viral factors</span><span class="headingEndMark"> — </span>DHF can occur during infection with any of the four dengue serotypes; several prospective studies have suggested that the risk is highest with dengue-2 viruses [<a href="#rid15">15,61-63</a>]. Genetic analyses of DENV isolates from the Western hemisphere strongly suggest that DHF only occurs during infection with viruses that fall into specific genotypes within each dengue serotype [<a href="#rid64">64,65</a>]. These "virulent" genotypes were originally detected in Southeast Asia but are now widespread. Several studies have suggested that "virulent" and "avirulent" genotypes differ in their ability to replicate in monocytic cells [<a href="#rid66">66,67</a>], but it is not clear that this difference in in vitro replication is the factor responsible for virulence.</p><p class="headingAnchor" id="H10"><span class="h2">Prior dengue exposure</span><span class="headingEndMark"> — </span>Multiple epidemiologic studies have shown that the risk of severe disease (DHF and DSS) is significantly higher during a secondary DENV infection than during a primary infection [<a href="#rid9">9,61,68,69</a>].</p><p>The increased risk of DHF in secondary DENV infections is felt to reflect the differences in immune responses between primary and secondary DENV infections described above: antibody-dependent enhancement of infection, enhanced immune complex formation, and/or accelerated T lymphocyte responses.</p><p>The increased risk for DHF associated with secondary DENV infections appears not to apply to infections with "avirulent" genotypes (see above). A prospective study in Peru found no cases of DHF or DSS during an outbreak of dengue-2 virus infections that was estimated to involve over 49,000 secondary infections in children [<a href="#rid65">65</a>]. At least 880 cases of DHF would have been expected based upon previous studies in Thailand. Furthermore, there are numerous documented cases of DHF occurring during primary infection, suggesting that differences in viral virulence, as discussed above, are also important [<a href="#rid1">1,15</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Age</span><span class="headingEndMark"> — </span>The risk for DHF appears to decline with age, especially after age 11 years. During the 1981 epidemic of DHF in Cuba, the modal age of DHF cases and deaths was 4 years, although the frequency of secondary dengue-2 infections was similar in those 4 to 40 years of age [<a href="#rid70">70,71</a>].</p><p>A specific population at higher risk for DHF in endemic areas is infants, particularly those between 6 and 12 months of age. These children acquire DENV-specific antibodies transplacentally and become susceptible to primary DENV infection when antibody levels decline below the neutralization threshold [<a href="#rid72">72</a>]. This observation is taken to support the hypothesis of antibody-dependent enhancement of infection as a primary factor in determining the risk for DHF. A direct correlation between antibody-dependent enhancement (ADE) activity of preinfection serum and the severity of infection has not been demonstrated, however [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Nutritional status</span><span class="headingEndMark"> — </span>Some studies have reported that, unlike other infectious diseases, DHF and DSS are less common in malnourished children than in well-nourished children [<a href="#rid74">74</a>], and this has been taken to reflect the role of the immune response in disease pathogenesis. A systematic review found no consistent association with nutritional status, however [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Epidemiologic studies in Cuba showed that DHF occurred more often in White persons than in Black persons [<a href="#rid71">71</a>], and a similar genetic resistance to DHF in Black individuals has been reported from Haiti [<a href="#rid76">76</a>]. Racial differences have been described in viral replication in primary monocytes and in the level of dengue serotype-cross-reactive T cell responses [<a href="#rid77">77</a>], but it is unclear if either of these explains the genetic association.</p><p>Genome-wide association studies conducted in Vietnam [<a href="#rid78">78,79</a>] and Thailand [<a href="#rid80">80</a>] have found significant genetic associations of two single-nucleotide polymorphisms, one in the major histocompatibility complex class I polypeptide-related sequence B (<em>MICB</em>) gene and one in the phospholipase C epsilon 1 (<em>PLCE1</em>) genes, with both dengue shock syndrome and less severe dengue. The mechanisms for these associations have not been defined.</p><p>In focused studies, DHF has been associated with specific human leukocyte antigen genes [<a href="#rid81">81,82</a>], with blood group [<a href="#rid83">83</a>], and with polymorphisms of tumor necrosis factor-alpha, vitamin D, Fc gamma IIa, and DC-SIGN genes [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H14"><span class="h1">PATHOPHYSIOLOGY OF DISEASE MANIFESTATIONS</span></p><p class="headingAnchor" id="H15"><span class="h2">Capillary leak syndrome</span><span class="headingEndMark"> — </span>Plasma leakage, due to an increase in capillary permeability, is a cardinal feature of dengue hemorrhagic fever (DHF) but is absent in dengue fever (DF). The enhanced capillary permeability appears to be due to endothelial cell dysfunction rather than injury, as electron microscopy demonstrated a widening of the endothelial tight junctions [<a href="#rid84">84</a>]. DENV infects human endothelial cells in vitro and causes cellular activation [<a href="#rid85">85</a>]. Additionally, soluble NS1 protein, which can be detected in the serum during acute infection, has been reported to bind to endothelial cells, to activate cells through toll-like receptor 4 signaling, to induce endothelial permeability and disrupt the glycocalyx, and to serve as a target for antibody binding and complement activation [<a href="#rid86">86-88</a>]. However, the effects on endothelial cell function during infection are thought more likely to be indirectly caused by DENV infection for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Histologic studies show little structural damage to capillaries [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection of endothelial cells by DENV is not apparent in tissues obtained at autopsy [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased capillary permeability is transient, with rapid resolution and no residual pathology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maximal plasma leakage occurs several days after the peak of circulating levels of viral RNA or NS1 protein, during the stage of rapid immune clearance.</p><p></p><p>Most investigations have focused on the hypothesis that circulating factors induce the transient increase in capillary permeability. Multiple mediators are likely to be involved in vivo, and interactions between these different factors have been demonstrated in experimental animals. Nitric oxide has been associated with increased vascular permeability and severe dengue in two prospective studies in Asia [<a href="#rid90">90,91</a>]. However, the most important mediators are still thought to include tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-2, IL-8, vascular endothelial growth factor (VEGF), and complement [<a href="#rid92">92</a>]. The sources of these cytokines have been proposed to include virus-infected monocytes, dendritic cells and mast cells, activated platelets, and DENV-specific CD4 and CD8 T lymphocytes.</p><p>Elevated serum levels of TNF-alpha, IL-8, IFN-gamma, IL-2, and free VEGF have been observed in patients with DHF [<a href="#rid92">92</a>]. Other studies have found reduced serum levels of the complement proteins C3 and C5 in patients with DHF, with a corresponding increase in the serum concentrations of anaphylatoxins C3a and C5a [<a href="#rid93">93,94</a>].</p><p>It is difficult to detect elevated cytokine levels in the circulation, because of the short half-life of these molecules. Analysis of more stable markers of immune activation has provided additional, although indirect, support for the immunopathogenesis model of plasma leakage. Several studies have shown that children with DHF have elevated circulating levels of the soluble forms of CD8, CD4, IL-2 receptors, and TNF receptors [<a href="#rid92">92</a>]. Increased plasma concentrations of soluble TNF receptor II were found to correlate with the subsequent development of and with the magnitude of plasma leakage into the pleural space. The intensity of the immune response may ultimately be determined by the level of viral replication, however, as one study found that the plasma viremia titer was the strongest independent factor that correlated with plasma leakage [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Blood and bone marrow</span><span class="headingEndMark"> — </span>Leukopenia, thrombocytopenia, and a hemorrhagic diathesis are the typical hematologic findings in DENV infections. Leukopenia is apparent early in illness and is of similar degree in DHF and dengue fever [<a href="#rid95">95</a>]. It is thought to represent a direct effect of DENV on the bone marrow. Bone marrow biopsies of children in Thailand with DHF revealed suppression of hematopoiesis early in the illness, with marrow recovery and hypercellularity in the late stage and during early clinical recovery [<a href="#rid96">96</a>]. In vitro studies have shown that DENV infects human bone marrow stromal cells and hematopoietic progenitor cells [<a href="#rid97">97,98</a>] and inhibits progenitor cell growth [<a href="#rid99">99</a>].</p><p>Some degree of thrombocytopenia is common in both dengue fever and DHF, but marked thrombocytopenia (&lt;100,000 platelets/mm<sup>3</sup>) is one of the criteria used to define DHF. Multiple factors are thought to contribute to the fall in platelet count, which is most severe late in the illness [<a href="#rid95">95</a>]. Bone marrow suppression may play a role, but platelet destruction is probably more important. In one study, 10 of 11 Thai children with DHF had a shortened platelet survival time, ranging from 6.5 to 53 hours [<a href="#rid100">100</a>]. Adsorption of dengue virions or virus-antibody immune complexes to the platelet surface, with subsequent activation of complement, are thought to be responsible for the platelet destruction.</p><p>Manifestations of the hemorrhagic diathesis in DENV infections range from a positive tourniquet test to life-threatening hemorrhage. Fatal DHF may be associated with diffuse petechial hemorrhages involving the stomach, skin, heart, intestine, and lungs [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a>.)</p><p>Despite the nomenclature, however, the occurrence of hemorrhage does not define DHF as compared with dengue fever since a positive tourniquet test may occur with equal frequency in the two disorders [<a href="#rid95">95</a>]. Several different mechanisms, possibly acting synergistically, contribute to bleeding tendency of DENV infections. Both the vasculopathy and thrombocytopenia described above create a predisposition to bleeding.</p><p>Endothelial cell activation and injury and activation of coagulation and fibrinolysis have been reported in dengue, particularly in severe infections. Abnormalities that have been described include increased numbers of circulating endothelial cells [<a href="#rid101">101</a>], elevated levels of von Willebrand factor, tissue factor, tissue plasminogen activator, and platelet activator inhibitor [<a href="#rid102">102</a>], and an increased fractional catabolic rate of fibrinogen [<a href="#rid103">103</a>]. However, most of these findings are based on small studies and comparison with non-dengue controls. Frank coagulopathy is uncommon except in patients with shock.</p><p>A final etiologic factor may be molecular mimicry between dengue viral proteins and coagulation factors. One study of 88 Tahitian children with DENV infection found that antibody responses to homologous peptides derived from the DENV E protein cross-reacted with plasminogen; these antibodies correlated with the occurrence of hemorrhagic signs (including petechiae) but not with thrombocytopenia or shock [<a href="#rid104">104</a>]. Another study reported that monoclonal antibodies directed at the DENV NS1 protein bound in vitro to human fibrinogen, platelets, and endothelial cells and induced hemorrhage in mice [<a href="#rid105">105</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Liver</span><span class="headingEndMark"> — </span>Elevations of serum aminotransferases that are usually mild are common in DENV infections [<a href="#rid95">95</a>]. Typical pathologic findings in the livers of fatal cases of dengue include hepatocellular necrosis and Councilman bodies with relatively little inflammatory cell infiltration, similar to the findings in early yellow fever virus infection [<a href="#rid89">89</a>]. The pathologic similarities between these two diseases and the relatively frequent isolation of DENV from liver tissues of fatal cases suggest that liver injury is directly mediated by DENV infection of hepatocytes and Kupffer cells. DENV has been shown to infect and induce apoptosis in a human hepatoma cell line in vitro [<a href="#rid106">106</a>]. However, immune-mediated hepatocyte injury is a potential alternative mechanism.</p><p class="headingAnchor" id="H18"><span class="h2">Central nervous system</span><span class="headingEndMark"> — </span>Rare cases of encephalopathy have been attributed to DENV infections. True encephalitis has been reported, with detection of DENV in brain tissue [<a href="#rid107">107</a>], but this is clearly the exception in humans. In one series of 100 fatal cases of dengue, no evidence of central nervous system inflammation was found [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H99089067"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83159.html" rel="external">"Patient education: Dengue fever (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2847719"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vector</strong> – DENV is introduced into the skin when an infected mosquito, most commonly <em>Aedes aegypti</em>, takes a blood meal from a susceptible host. (See <a class="local">'Early events'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Replication cycle</strong> – Dengue viruses (DENVs) are small, enveloped viruses that are members of the family Flaviviridae genus <em>Flavivirus</em>. Viral replication involves the following steps: attachment to the cell surface, cellular entry, translation of viral proteins, replication of the viral RNA genome, formation of virions by encapsidation, and cellular release. (See <a class="local">'The dengue virus replication cycle'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dissemination</strong> – Viremia is detectable in humans 6 to 18 hours before the onset of symptoms and ends as the fever resolves. (See <a class="local">'Dissemination'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune response</strong> – Both innate and adaptive immune responses induced by DENV infection are likely to play a role in the clearance of infection. (See <a class="local">'Immune response and viral clearance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serotype immunity</strong> – Infection with one of the four serotypes of DENV (primary infection) provides long-lasting immunity to infection with a virus of the same serotype [<a href="#rid13">13</a>]. However, immunity to the other dengue serotypes is transient, and individuals can subsequently be infected with another dengue serotype (secondary infection). (See <a class="local">'Primary versus secondary infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enhanced infection</strong> – Antibodies to proteins on the DENV surface can cause increased infection of cells bearing immunoglobulin receptors, a phenomenon known as antibody-dependent enhancement of infection. (See <a class="local">'Immune response and viral clearance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determinants of severe illness</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocytic response</strong> – <strong>The</strong> severity of dengue disease has been correlated with both the level and quality of the DENV-specific T lymphocyte responses. (See <a class="local">'Primary versus secondary infection'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Serotype</strong> – Although dengue hemorrhagic fever (DHF) can occur during infection with any of the four dengue serotypes, several prospective studies have suggested that the risk is highest with dengue-2 viruses. (See <a class="local">'Factors influencing disease severity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Secondary infection</strong> – Epidemiologic studies have shown that the risk of severe disease is significantly higher during a secondary DENV infection than during a primary infection. (See <a class="local">'Prior dengue exposure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis of severe illness</strong> – Plasma leakage, due to an increase in capillary permeability, is a cardinal feature of DHF but is absent in dengue fever. The enhanced capillary permeability appears to be due to endothelial cell dysfunction rather than injury. (See <a class="local">'Pathophysiology of disease manifestations'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rico-Hesse R. Dengue virus evolution and virulence models. Clin Infect Dis 2007; 44:1462.</a></li><li><a class="nounderline abstract_t">Lok SM. The Interplay of Dengue Virus Morphological Diversity and Human Antibodies. Trends Microbiol 2016; 24:284.</a></li><li><a class="nounderline abstract_t">Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 2003; 100:6986.</a></li><li><a class="nounderline abstract_t">Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature 2004; 427:313.</a></li><li><a class="nounderline abstract_t">Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 2005; 3:13.</a></li><li><a class="nounderline abstract_t">Chen Y, Maguire T, Hileman RE, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997; 3:866.</a></li><li><a class="nounderline abstract_t">Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003; 197:823.</a></li><li><a class="nounderline abstract_t">Chen ST, Lin YL, Huang MT, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008; 453:672.</a></li><li><a class="nounderline abstract_t">Halstead SB. Dengue Antibody-Dependent Enhancement: Knowns and Unknowns. Microbiol Spectr 2014; 2.</a></li><li><a class="nounderline abstract_t">Marchette NJ, Halstead SB, Falkler WA Jr, et al. Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis 1973; 128:23.</a></li><li><a class="nounderline abstract_t">Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6:816.</a></li><li><a class="nounderline abstract_t">Kyle JL, Beatty PR, Harris E. Dengue virus infects macrophages and dendritic cells in a mouse model of infection. J Infect Dis 2007; 195:1808.</a></li><li><a class="nounderline abstract_t">SABIN AB. Research on dengue during World War II. Am J Trop Med Hyg 1952; 1:30.</a></li><li><a class="nounderline abstract_t">Endy TP, Wang D, Polhemus ME, et al. A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain. J Infect Dis 2021; 223:258.</a></li><li><a class="nounderline abstract_t">Vaughn DW, Green S, Kalayanarooj S, et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997; 176:322.</a></li><li><a class="nounderline abstract_t">Scott RM, Nisalak A, Cheamudon U, et al. Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever. J Infect Dis 1980; 141:1.</a></li><li><a class="nounderline abstract_t">King AD, Nisalak A, Kalayanrooj S, et al. B cells are the principal circulating mononuclear cells infected by dengue virus. Southeast Asian J Trop Med Public Health 1999; 30:718.</a></li><li><a class="nounderline abstract_t">Durbin AP, Vargas MJ, Wanionek K, et al. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 2008; 376:429.</a></li><li><a class="nounderline abstract_t">Srikiatkhachorn A, Wichit S, Gibbons RV, et al. Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status. PLoS One 2012; 7:e51335.</a></li><li><a class="nounderline abstract_t">Rosen L, Khin MM, U T. Recovery of virus from the liver of children with fatal dengue: reflections on the pathogenesis of the disease and its possible analogy with that of yellow fever. Res Virol 1989; 140:351.</a></li><li><a class="nounderline abstract_t">Boonpucknavig S, Boonpucknavig V, Bhamarapravati N, Nimmannitya S. Immunofluorescence study of skin rash in patients with dengue hemorrhagic fever. Arch Pathol Lab Med 1979; 103:463.</a></li><li><a class="nounderline abstract_t">Hall WC, Crowell TP, Watts DM, et al. Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis. Am J Trop Med Hyg 1991; 45:408.</a></li><li><a class="nounderline abstract_t">Jessie K, Fong MY, Devi S, et al. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 2004; 189:1411.</a></li><li><a class="nounderline abstract_t">Fresh JW, Reyes V, Clarke EJ, Uylangco CV. Philippine hemorrhagic fever: a clinical, laboratory, and necropsy study. J Lab Clin Med 1969; 73:451.</a></li><li><a class="nounderline abstract_t">Schmidt AC. Response to dengue fever--the good, the bad, and the ugly? N Engl J Med 2010; 363:484.</a></li><li><a class="nounderline abstract_t">Castillo Ramirez JA, Urcuqui-Inchima S. Dengue Virus Control of Type I IFN Responses: A History of Manipulation and Control. J Interferon Cytokine Res 2015; 35:421.</a></li><li><a class="nounderline abstract_t">Libraty DH, Endy TP, Houng HS, et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002; 185:1213.</a></li><li><a class="nounderline abstract_t">Kurane I, Hebblewaite D, Brandt WE, Ennis FA. Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity. J Virol 1984; 52:223.</a></li><li><a class="nounderline abstract_t">Muñoz-Jordan JL, Sánchez-Burgos GG, Laurent-Rolle M, García-Sastre A. Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 2003; 100:14333.</a></li><li><a class="nounderline abstract_t">Jones M, Davidson A, Hibbert L, et al. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 2005; 79:5414.</a></li><li><a class="nounderline abstract_t">Simmons CP, Popper S, Dolocek C, et al. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J Infect Dis 2007; 195:1097.</a></li><li><a class="nounderline abstract_t">Popper SJ, Gordon A, Liu M, et al. Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children. PLoS Negl Trop Dis 2012; 6:e1966.</a></li><li><a class="nounderline abstract_t">Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol 1987; 68 ( Pt 3):853.</a></li><li><a class="nounderline abstract_t">Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500.</a></li><li><a class="nounderline abstract_t">Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008; 10:e12.</a></li><li><a class="nounderline abstract_t">Halstead SB. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody. J Infect Dis 1979; 140:527.</a></li><li><a class="nounderline abstract_t">Goncalvez AP, Engle RE, St Claire M, et al. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 2007; 104:9422.</a></li><li><a class="nounderline abstract_t">Balsitis SJ, Williams KL, Lachica R, et al. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 2010; 6:e1000790.</a></li><li><a class="nounderline abstract_t">Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 2010; 328:745.</a></li><li><a class="nounderline abstract_t">Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011; 11:532.</a></li><li><a class="nounderline abstract_t">Kontny U, Kurane I, Ennis FA. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. J Virol 1988; 62:3928.</a></li><li><a class="nounderline abstract_t">Anderson KB, Gibbons RV, Cummings DA, et al. A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. J Infect Dis 2014; 209:360.</a></li><li><a class="nounderline abstract_t">Montoya M, Gresh L, Mercado JC, et al. Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year. PLoS Negl Trop Dis 2013; 7:e2357.</a></li><li><a class="nounderline abstract_t">Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. J Infect Dis 1973; 128:15.</a></li><li><a class="nounderline abstract_t">Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2.</a></li><li><a class="nounderline abstract_t">Murgue B, Roche C, Chungue E, Deparis X. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J Med Virol 2000; 60:432.</a></li><li><a class="nounderline abstract_t">Wang WK, Chen HL, Yang CF, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 2006; 43:1023.</a></li><li><a class="nounderline abstract_t">Kuberski T, Rosen L, Reed D, Mataika J. Clinical and laboratory observations on patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji. Am J Trop Med Hyg 1977; 26:775.</a></li><li><a class="nounderline abstract_t">Sudiro TM, Zivny J, Ishiko H, et al. Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction. J Med Virol 2001; 63:29.</a></li><li><a class="nounderline abstract_t">Katzelnick LC, Gresh L, Halloran ME, et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 2017; 358:929.</a></li><li><a class="nounderline abstract_t">Salje H, Cummings DAT, Rodriguez-Barraquer I, et al. Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 2018; 557:719.</a></li><li><a class="nounderline abstract_t">Green S, Pichyangkul S, Vaughn DW, et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis 1999; 180:1429.</a></li><li><a class="nounderline abstract_t">Mongkolsapaya J, Dejnirattisai W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9:921.</a></li><li><a class="nounderline abstract_t">Zivna I, Green S, Vaughn DW, et al. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 2002; 168:5959.</a></li><li><a class="nounderline abstract_t">Simmons CP, Dong T, Chau NV, et al. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J Virol 2005; 79:5665.</a></li><li><a class="nounderline abstract_t">Friberg H, Bashyam H, Toyosaki-Maeda T, et al. Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans. Sci Rep 2011; 1:51.</a></li><li><a class="nounderline abstract_t">Dung NT, Duyen HT, Thuy NT, et al. Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue. J Immunol 2010; 184:7281.</a></li><li><a class="nounderline abstract_t">Mangada MM, Endy TP, Nisalak A, et al. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis 2002; 185:1697.</a></li><li><a class="nounderline abstract_t">Hatch S, Endy TP, Thomas S, et al. Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 2011; 203:1282.</a></li><li><a class="nounderline abstract_t">Friberg H, Beaumier CM, Park S, et al. Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection. PLoS Negl Trop Dis 2018; 12:e0006975.</a></li><li><a class="nounderline abstract_t">Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172.</a></li><li><a class="nounderline abstract_t">Sangkawibha N, Rojanasuphot S, Ahandrik S, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 1984; 120:653.</a></li><li><a class="nounderline abstract_t">Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 2009; 22:564.</a></li><li><a class="nounderline abstract_t">Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230:244.</a></li><li><a class="nounderline abstract_t">Watts DM, Porter KR, Putvatana P, et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999; 354:1431.</a></li><li><a class="nounderline abstract_t">Pryor MJ, Carr JM, Hocking H, et al. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 2001; 65:427.</a></li><li><a class="nounderline abstract_t">Cologna R, Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003; 77:3929.</a></li><li><a class="nounderline abstract_t">Guzmán MG, Kourí G, Martínez E, et al. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull Pan Am Health Organ 1987; 21:270.</a></li><li><a class="nounderline abstract_t">Thein S, Aung MM, Shwe TN, et al. Risk factors in dengue shock syndrome. Am J Trop Med Hyg 1997; 56:566.</a></li><li><a class="nounderline abstract_t">Kourí G, Guzmán MG, Bravo J. Hemorrhagic dengue in Cuba: history of an epidemic. Bull Pan Am Health Organ 1986; 20:24.</a></li><li><a class="nounderline abstract_t">Guzmán MG, Kouri GP, Bravo J, et al. Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg 1990; 42:179.</a></li><li><a class="nounderline abstract_t">Simmons CP, Chau TN, Thuy TT, et al. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 2007; 196:416.</a></li><li><a class="nounderline abstract_t">Libraty DH, Acosta LP, Tallo V, et al. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2009; 6:e1000171.</a></li><li><a class="nounderline abstract_t">Thisyakorn U, Nimmannitya S. Nutritional status of children with dengue hemorrhagic fever. Clin Infect Dis 1993; 16:295.</a></li><li><a class="nounderline abstract_t">Trang NT, Long NP, Hue TT, et al. Association between nutritional status and dengue infection: a systematic review and meta-analysis. BMC Infect Dis 2016; 16:172.</a></li><li><a class="nounderline abstract_t">Halstead SB, Streit TG, Lafontant JG, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg 2001; 65:180.</a></li><li><a class="nounderline abstract_t">de la C Sierra B, Kourí G, Guzmán MG. Race: a risk factor for dengue hemorrhagic fever. Arch Virol 2007; 152:533.</a></li><li><a class="nounderline abstract_t">Khor CC, Chau TN, Pang J, et al. Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1. Nat Genet 2011; 43:1139.</a></li><li><a class="nounderline abstract_t">Whitehorn J, Chau TN, Nguyet NM, et al. Genetic variants of MICB and PLCE1 and associations with non-severe dengue. PLoS One 2013; 8:e59067.</a></li><li><a class="nounderline abstract_t">Dang TN, Naka I, Sa-Ngasang A, et al. A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome. BMC Med Genet 2014; 15:58.</a></li><li><a class="nounderline abstract_t">Xavier-Carvalho C, Cardoso CC, de Souza Kehdy F, et al. Host genetics and dengue fever. Infect Genet Evol 2017; 56:99.</a></li><li><a class="nounderline abstract_t">Stephens HA. HLA and other gene associations with dengue disease severity. Curr Top Microbiol Immunol 2010; 338:99.</a></li><li><a class="nounderline abstract_t">Kalayanarooj S, Gibbons RV, Vaughn D, et al. Blood group AB is associated with increased risk for severe dengue disease in secondary infections. J Infect Dis 2007; 195:1014.</a></li><li><a class="nounderline abstract_t">Sahaphong S, Riengrojpitak S, Bhamarapravati N, Chirachariyavej T. Electron microscopic study of the vascular endothelial cell in dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1980; 11:194.</a></li><li><a class="nounderline abstract_t">Srikiatkhachorn A, Ajariyakhajorn C, Endy TP, et al. Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever. J Virol 2007; 81:1592.</a></li><li><a class="nounderline abstract_t">Watterson D, Modhiran N, Young PR. The many faces of the flavivirus NS1 protein offer a multitude of options for inhibitor design. Antiviral Res 2016; 130:7.</a></li><li><a class="nounderline abstract_t">Beatty PR, Puerta-Guardo H, Killingbeck SS, et al. Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination. Sci Transl Med 2015; 7:304ra141.</a></li><li><a class="nounderline abstract_t">Puerta-Guardo H, Glasner DR, Harris E. Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability. PLoS Pathog 2016; 12:e1005738.</a></li><li><a class="nounderline abstract_t">Bhamarapravati N, Tuchinda P, Boonyapaknavik V. Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann Trop Med Parasitol 1967; 61:500.</a></li><li><a class="nounderline abstract_t">Thein TL, Wong J, Leo YS, et al. Association Between Increased Vascular Nitric Oxide Bioavailability and Progression to Dengue Hemorrhagic Fever in Adults. J Infect Dis 2015; 212:711.</a></li><li><a class="nounderline abstract_t">Yacoub S, Lam PK, Huynh TT, et al. Endothelial Nitric Oxide Pathways in the Pathophysiology of Dengue: A Prospective Observational Study. Clin Infect Dis 2017; 65:1453.</a></li><li><a class="nounderline abstract_t">Srikiatkhachorn A, Green S. Markers of dengue disease severity. Curr Top Microbiol Immunol 2010; 338:67.</a></li><li><a class="nounderline abstract_t">Malasit P. Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health 1987; 18:316.</a></li><li><a class="nounderline abstract_t">Nascimento EJ, Silva AM, Cordeiro MT, et al. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One 2009; 4:e6782.</a></li><li><a class="nounderline abstract_t">Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.</a></li><li><a class="nounderline abstract_t">BIERMAN HR, NELSON ER. HEMATODEPRESSIVE VIRUS DISEASES OF THAILAND. Ann Intern Med 1965; 62:867.</a></li><li><a class="nounderline abstract_t">Rothwell SW, Putnak R, La Russa VF. Dengue-2 virus infection of human bone marrow: characterization of dengue-2 antigen-positive stromal cells. Am J Trop Med Hyg 1996; 54:503.</a></li><li><a class="nounderline abstract_t">Nakao S, Lai CJ, Young NS. Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood 1989; 74:1235.</a></li><li><a class="nounderline abstract_t">Murgue B, Cassar O, Guigon M, Chungue E. Dengue virus inhibits human hematopoietic progenitor growth in vitro. J Infect Dis 1997; 175:1497.</a></li><li><a class="nounderline abstract_t">Mitrakul C, Poshyachinda M, Futrakul P, et al. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26:975.</a></li><li><a class="nounderline abstract_t">Cardier JE, Rivas B, Romano E, et al. Evidence of vascular damage in dengue disease: demonstration of high levels of soluble cell adhesion molecules and circulating endothelial cells. Endothelium 2006; 13:335.</a></li><li><a class="nounderline abstract_t">Sosothikul D, Seksarn P, Pongsewalak S, et al. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost 2007; 97:627.</a></li><li><a class="nounderline abstract_t">Srichaikul T, Nimmanitaya S, Artchararit N, et al. Fibrinogen metabolism and disseminated intravascular coagulation in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26:525.</a></li><li><a class="nounderline abstract_t">Chungue E, Poli L, Roche C, et al. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J Infect Dis 1994; 170:1304.</a></li><li><a class="nounderline abstract_t">Falconar AK. The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. Arch Virol 1997; 142:897.</a></li><li><a class="nounderline abstract_t">Marianneau P, Cardona A, Edelman L, et al. Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death. J Virol 1997; 71:3244.</a></li><li><a class="nounderline abstract_t">Solomon T, Dung NM, Vaughn DW, et al. Neurological manifestations of dengue infection. Lancet 2000; 355:1053.</a></li></ol></div><div id="topicVersionRevision">Topic 3029 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17479944" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Dengue virus evolution and virulence models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747581" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Interplay of Dengue Virus Morphological Diversity and Human Antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12759475" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A ligand-binding pocket in the dengue virus envelope glycoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14737159" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Structure of the dengue virus envelope protein after membrane fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15608696" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A structural perspective of the flavivirus life cycle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256277" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12682107" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18496526" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : CLEC5A is critical for dengue-virus-induced lethal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26104444" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dengue Antibody-Dependent Enhancement: Knowns and Unknowns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4198025" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10888933" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human skin Langerhans cells are targets of dengue virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17492597" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dengue virus infects macrophages and dendritic cells in a mouse model of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14903434" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Research on dengue during World War II.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32572470" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237696" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dengue in the early febrile phase: viremia and antibody responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7365271" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Isolation of dengue viruses from peripheral blood leukocytes of patients with hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10928366" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : B cells are the principal circulating mononuclear cells infected by dengue virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18452966" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284680" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2772416" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Recovery of virus from the liver of children with fatal dengue: reflections on the pathogenesis of the disease and its possible analogy with that of yellow fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/380510" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunofluorescence study of skin rash in patients with dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1951849" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Demonstration of yellow fever and dengue antigens in formalin-fixed paraffin-embedded human liver by immunohistochemical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15073678" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5766189" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Philippine hemorrhagic fever: a clinical, laboratory, and necropsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20818870" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Response to dengue fever--the good, the bad, and the ugly?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25629430" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dengue Virus Control of Type I IFN Responses: A History of Manipulation and Control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12001037" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6207308" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lysis of dengue virus-infected cells by natural cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14612562" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Inhibition of interferon signaling by dengue virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827155" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17357045" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23285306" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Temporal dynamics of the transcriptional response to dengue virus infection in Nicaraguan children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819700" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7811870" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Antibody-dependent enhancement of infection and the pathogenesis of viral disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18471342" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/117061" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517625" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20168989" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20448183" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cross-reacting antibodies enhance dengue virus infection in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21760609" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2459406" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964110" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23951377" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4198024" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10608744" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10686027" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16983615" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/889017" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and laboratory observations on patients with primary and secondary dengue type 1 infections with hemorrhagic manifestations in Fiji.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11130884" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Analysis of plasma viral RNA levels during acute dengue virus infection using quantitative competitor reverse transcription-polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29097492" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Antibody-dependent enhancement of severe dengue disease in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29795354" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reconstruction of antibody dynamics and infection histories to evaluate dengue risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10515800" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12808447" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023403" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15827181" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22355570" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cross-reactivity and expansion of dengue-specific T cells during acute primary and secondary infections in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20483770" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Timing of CD8+ T cell responses in relation to commencement of capillary leakage in children with dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085313" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21335561" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30557313" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Protective versus pathologic pre-exposure cytokine profiles in dengue virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341519" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A prospective study of dengue infections in Bangkok.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6496446" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822889" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Dengue virus pathogenesis: an integrated view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9143280" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10543670" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11716094" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12634353" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : American genotype structures decrease dengue virus output from human monocytes and dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3442718" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180609" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Risk factors in dengue shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3768589" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hemorrhagic dengue in Cuba: history of an epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2316788" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597456" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Maternal antibody and viral factors in the pathogenesis of dengue virus in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19859541" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8443312" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Nutritional status of children with dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27097934" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Association between nutritional status and dengue infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11561700" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106622" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Race: a risk factor for dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22001756" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Genome-wide association study identifies susceptibility loci for dengue shock syndrome at MICB and PLCE1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536857" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Genetic variants of MICB and PLCE1 and associations with non-severe dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24884822" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A replication study confirms the association of GWAS-identified SNPs at MICB and PLCE1 in Thai patients with dengue shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133029" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Host genetics and dengue fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19802581" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : HLA and other gene associations with dengue disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17330792" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Blood group AB is associated with increased risk for severe dengue disease in secondary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7434071" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Electron microscopic study of the vascular endothelial cell in dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17151115" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Virus-induced decline in soluble vascular endothelial growth receptor 2 is associated with plasma leakage in dengue hemorrhagic Fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26944216" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The many faces of the flavivirus NS1 protein offer a multitude of options for inhibitor design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26355030" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27416066" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Dengue Virus NS1 Disrupts the Endothelial Glycocalyx, Leading to Hyperpermeability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5634140" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25732810" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Association Between Increased Vascular Nitric Oxide Bioavailability and Progression to Dengue Hemorrhagic Fever in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673038" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Endothelial Nitric Oxide Pathways in the Pathophysiology of Dengue: A Prospective Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19802579" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Markers of dengue disease severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3501613" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Complement and dengue haemorrhagic fever/shock syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19707565" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Alternative complement pathway deregulation is correlated with dengue severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9237695" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Early clinical and laboratory indicators of acute dengue illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14283387" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : HEMATODEPRESSIVE VIRUS DISEASES OF THAILAND.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8644906" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Dengue-2 virus infection of human bone marrow: characterization of dengue-2 antigen-positive stromal cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2765663" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9180193" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Dengue virus inhibits human hematopoietic progenitor growth in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/907057" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hemostatic and platelet kinetic studies in dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17090406" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Evidence of vascular damage in dengue disease: demonstration of high levels of soluble cell adhesion molecules and circulating endothelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17393026" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/869104" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Fibrinogen metabolism and disseminated intravascular coagulation in dengue hemorrhagic fever.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7963733" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9191856" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060688" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Dengue virus replication in human hepatoma cells activates NF-kappaB which in turn induces apoptotic cell death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10744091" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Neurological manifestations of dengue infection.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
